Effectiveness of Two Aspirin Doses for Prevention of Hypertensive Disorders of Pregnancy: ASPIRIN TRIAL

Recruiting now · Phase 4

Conditions studied: Hypertensive Disorders of Pregnancy, Preeclampsia, Gestational Hypertension

In brief

The overall goal of this large, pragmatic, comparative effectiveness trial is to test the hypothesis that among at-risk individuals, 162 mg/day aspirin is superior to 81 mg/day in preventing Hypertensive disorders of pregnancy (HDP), and that there are multiple factors associated with adherence with aspirin therapy that will be important to identify to enable optimal implementation of study findings and population-level benefits.

Key facts

Study ID

NCT06468202

Run by

Ohio State University

People needed

10742

Starts

2024-10-18

Expected to finish

2030-02-01

Last updated by the study team

2026-05-04

Who can join

Age: 14 and older, up to 35. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• live intrauterine gestation ≤16 6/7 weeks gestational age based on best clinical obstetric estimate,
• age 14 years or older and able to provide informed consent,
• at least one of the following high-risk criteria: i) any prior pregnancy complicated by preeclampsia ii) current pregnancy complicated by chronic hypertension diagnosed before randomization (ACOG) iii) pre-gestational diabetes (on medication for diabetes prior to pregnancy, or diabetes is diagnosed prior to randomization with hemoglobin A1C of 6.5% or greater or abnormal 3-hour glucose tolerance test) iv) twin gestation (including higher order pregnancy reduced to twins prior to 14 weeks) v) chronic kidney disease vi) autoimmune disease (e.g., antiphospholipid syndrome, systemic lupus erythematous)
• or two or more moderate-risk criteria for HDP (per USPSTF), i) nulliparity (no prior delivery at or after 20 weeks 0 days of gestation) ii) obesity (body mass index ≥30 kg/m2 at time of randomization) iii) age ≥35 years (at time of expected estimated due date) iv) Black race v) low income vi) personal risk factors (previous pregnancy with low birth weight or SGA infant, previous adverse pregnancy outcome [unexplained stillbirth], placental abruption, interval >10 years between pregnancies) vii) Family history of preeclampsia (i.e., mother or sister) viii) In vitro fertilization
• patient not currently on aspirin OR patient on aspirin for obstetrical indications (e.g., related to IVF, or HDP) and: i- randomized before 130/7 weeks gestation, or ii- randomized on or after 13 0/7 weeks gestation and started aspirin within 2 weeks prior to randomization (e.g., aspirin started for HDP prevention at 12 0/7 weeks and patient randomized at 13 2/7 weeks).

You may not qualify if…

• known allergy or hypersensitivity to aspirin or any medical condition where aspirin is contraindicated (e.g., active peptic ulcer disease, nasal polyps, NSAID-induced asthma, active gastrointestinal bleeding, known G6PD deficiency, severe hepatic dysfunction, bleeding disorders, history of bariatric surgery),
• current or planned aspirin use in pregnancy for non-obstetrical indication (e.g., prior stroke/prior myocardial infraction),
• age < 14 years,
• involuntarily confined or detained,
• considered as having a diminished decision-making capacity,
• obstetrical ultrasound suspicious for major congenital abnormality, known or suspected fetal aneuploidy, fetal demise, or planned pregnancy termination,
• participation in another trial that affects the primary outcome, without prior approval of the PI,
• plan to deliver at an outside participating site with inability to obtain medical records,
• monoamniotic twin gestation because of the risk of fetal demise and preterm delivery,
• participation in this trial in prior pregnancy,
• triplet or higher order pregnancy.

Where it is running

• University of Alabama at Birmingham — Birmingham, Alabama, United States (enrolling)
• Cedars Sinai Medical Center — Los Angeles, California, United States (enrolling)
• University of California, San Francisco — San Francisco, California, United States (enrolling)
• Northwestern University — Chicago, Illinois, United States (enrolling)
• University of Mississippi — Jackson, Mississippi, United States (enrolling)
• University of New Mexico — Albuquerque, New Mexico, United States (enrolling)
• Columbia University — New York, New York, United States (enrolling)
• University of North Carolina, Chapel Hill — Chapel Hill, North Carolina, United States (enrolling)
• The Ohio State University Wexner Medical Center OB/GYN Maternal and Fetal Medicine — Columbus, Ohio, United States (enrolling)
• University of Pittsburg Magee — Pittsburgh, Pennsylvania, United States (enrolling)
• Brown University — Providence, Rhode Island, United States (enrolling)
• University of Texas, Houston — Houston, Texas, United States (enrolling)
• University of Utah — Salt Lake City, Utah, United States (enrolling)
• Inova HealthSystem — Falls Church, Virginia, United States (enrolling)
• Eastern Virginia Medical School - Old Dominion University — Norfolk, Virginia, United States (enrolling)
• Medical College of Wisconsin — Milwaukee, Wisconsin, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.